Search

Your search keyword '"Puntoni, Matteo"' showing total 503 results
Start Over Author "Puntoni, Matteo"
503 results on '"Puntoni, Matteo"'

2. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Author

Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, and Tiseo, Marcello

Published
2024
Full Text
View/download PDF

3. Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study

Author

Bottoni, Gianluca, Fiz, Francesco, Puntoni, Matteo, Matteucci, Federica, Monti, Manuela, DeCensi, Andrea, Nanni, Oriana, Brain, Etienne, Alberini, Jean Louis, Dib, Bassam, Sacchetti, Gianmauro, Trimboli, Pierpaolo, Treglia, Giorgio, Harbeck, Nadia, Sola, Simona, Gennari, Alessandra, and Piccardo, Arnoldo

Published
2023
Full Text
View/download PDF

7. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Author

Leonetti, A, Perrone, F, Puntoni, M, Maglietta, G, Bordi, P, Bria, E, Vita, E, Gelsomino, F, De Giglio, A, Gelibter, A, Siringo, M, Mazzoni, F, Caliman, E, Genova, C, Bertolini, F, Guaitoli, G, Passiglia, F, Delcuratolo, M, Montrone, M, Cerea, G, Pasello, G, Roca, E, Belluomini, L, Cecere, F, Guida, A, Manzo, A, Adamo, V, Rastelli, F, Bulotta, A, Citarella, F, Toschi, L, Zoratto, F, Cortinovis, D, Berardi, R, Follador, A, Carta, A, Camerini, A, Salerno, F, Silva, R, Baldini, E, Cortellini, A, Brighenti, M, Santoni, M, Malorgio, F, Caminiti, C, Tiseo, M, Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, Tiseo, Marcello, Leonetti, A, Perrone, F, Puntoni, M, Maglietta, G, Bordi, P, Bria, E, Vita, E, Gelsomino, F, De Giglio, A, Gelibter, A, Siringo, M, Mazzoni, F, Caliman, E, Genova, C, Bertolini, F, Guaitoli, G, Passiglia, F, Delcuratolo, M, Montrone, M, Cerea, G, Pasello, G, Roca, E, Belluomini, L, Cecere, F, Guida, A, Manzo, A, Adamo, V, Rastelli, F, Bulotta, A, Citarella, F, Toschi, L, Zoratto, F, Cortinovis, D, Berardi, R, Follador, A, Carta, A, Camerini, A, Salerno, F, Silva, R, Baldini, E, Cortellini, A, Brighenti, M, Santoni, M, Malorgio, F, Caminiti, C, Tiseo, M, Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, and Tiseo, Marcello

Abstract

Purpose: The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC) in 33 Italian centers. Methods: The outcome measure was to evaluate overall survival (OS) in a real-world patient population. Secondary endpoints were: progression-free survival (PFS), objective response rate (ORR), duration of response (DoR) and incidence of treatment-related adverse events (AEs). Results: 1068 patients were enrolled at the time of data cut-off (January 31st, 2023), and 812 (76.0%) belonged to the retrospective cohort. Median age was 66 years (27−85), ECOG PS was ≥ 2 in 91 (8.6%) patients; 254 (23.8%) patients had brain metastases at baseline; 38 (3.6%) patients had tumor with PD-L1 expression ≥ 50%. After a median follow-up of 17.0 months (95% CI, 16.1–17.9), median OS was 16.1 months (95% CI, 14.4–18.8) and PFS was 9.9 months (95% CI, 8.8–11.2). Median DoR (n = 493) was 14.7 months (95% CI, 13.6–17.1). ORR was 43.4% (95% CI, 40.4–46.4). Any-grade AEs occurred in 636 (59.6%) patients and grade ≥ 3 in 253 (23.7%) patients. Most common grade ≥ 3 AEs were neutropenia (6.3%) and anemia (6.3%). Conclusions: First-line chemo-immunotherapy was effective and tolerable in this large, real-world Italian study of patients with advanced non-squamous NSCLC. Our results were in line with the KEYNOTE-189 registration study, also considering the low number of PD-L1 ≥ 50% patients included in our study.

Published
2024

8. Effects of COVID-19-targeted non-pharmaceutical interventions on pediatric emergency department use: a quasi-experimental study interrupted time-series analysis in North Italian hospitals, 2017 to 2022.

Author

Puntoni, Matteo, Maglietta, Giuseppe, Caminiti, Caterina, Miniaci, Angela, Lanari, Marcello, Caramelli, Fabio, Marchetti, Federico, De Fanti, Alessandro, Iughetti, Lorenzo, Biasucci, Giacomo, Suppiej, Agnese, Miceli, Andrea, Ghizzi, Chiara, Vergine, Gianluca, Aricò, Melodie, Stella, Marcello, and Esposito, Susanna

Published
2024
Full Text
View/download PDF

9. Effects of COVID-19-targeted non-pharmaceutical interventions on pediatric hospital admissions in North Italian hospitals, 2017 to 2022: a quasi-experimental study interrupted time-series analysis.

Author

Maglietta, Giuseppe, Puntoni, Matteo, Caminiti, Caterina, Pession, Andrea, Lanari, Marcello, Caramelli, Fabio, Marchetti, Federico, De Fanti, Alessandro, Iughetti, Lorenzo, Biasucci, Giacomo, Suppiej, Agnese, Miceli, Andrea, Ghizzi, Chiara, Vergine, Gianluca, Aricò, Melodie, Stella, Marcello, and Esposito, Susanna

Published
2024
Full Text
View/download PDF

12. Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial

Author

DeCensi, Andrea, Johansson, Harriet, Helland, Thomas, Puntoni, Matteo, Macis, Debora, Aristarco, Valentina, Caviglia, Silvia, Webber, Tania Buttiron, Briata, Irene Maria, D’Amico, Mauro, Serrano, Davide, Guerrieri-Gonzaga, Aliana, Bifulco, Ersilia, Hustad, Steinar, Søiland, Håvard, Boni, Luca, Bonanni, Bernardo, and Mellgren, Gunnar

Published
2021
Full Text
View/download PDF

22. Supplementary Figure S1 from Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial

Author

DeCensi, Andrea, primary, Puntoni, Matteo, primary, Guerrieri-Gonzaga, Aliana, primary, Cazzaniga, Massimiliano, primary, Serrano, Davide, primary, Lazzeroni, Matteo, primary, Vingiani, Andrea, primary, Gentilini, Oreste, primary, Petrera, Marilena, primary, Viale, Giuseppe, primary, Cuzick, Jack, primary, Bonanni, Bernardo, primary, and Pruneri, Giancarlo, primary

Published
2023
Full Text
View/download PDF

23. Data from Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial

Author

DeCensi, Andrea, primary, Puntoni, Matteo, primary, Guerrieri-Gonzaga, Aliana, primary, Cazzaniga, Massimiliano, primary, Serrano, Davide, primary, Lazzeroni, Matteo, primary, Vingiani, Andrea, primary, Gentilini, Oreste, primary, Petrera, Marilena, primary, Viale, Giuseppe, primary, Cuzick, Jack, primary, Bonanni, Bernardo, primary, and Pruneri, Giancarlo, primary

Published
2023
Full Text
View/download PDF

24. Data from A Randomized, Placebo-Controlled, Preoperative Trial of Allopurinol in Subjects with Colorectal Adenoma

Author

Puntoni, Matteo, primary, Branchi, Daniela, primary, Argusti, Alessandra, primary, Zanardi, Silvia, primary, Crosta, Cristiano, primary, Meroni, Emanuele, primary, Munizzi, Francesco, primary, Michetti, Paolo, primary, Coccia, Gianni, primary, De Roberto, Giuseppe, primary, Bandelloni, Roberto, primary, Turbino, Laura, primary, Minetti, Egle, primary, Mori, Marco, primary, Salvi, Sandra, primary, Boccardo, Simona, primary, Gatteschi, Beatrice, primary, Benelli, Roberto, primary, Sonzogni, Angelica, primary, and DeCensi, Andrea, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table S1 from Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial

Author

DeCensi, Andrea, primary, Puntoni, Matteo, primary, Guerrieri-Gonzaga, Aliana, primary, Cazzaniga, Massimiliano, primary, Serrano, Davide, primary, Lazzeroni, Matteo, primary, Vingiani, Andrea, primary, Gentilini, Oreste, primary, Petrera, Marilena, primary, Viale, Giuseppe, primary, Cuzick, Jack, primary, Bonanni, Bernardo, primary, and Pruneri, Giancarlo, primary

Published
2023
Full Text
View/download PDF

29. Commentary on This Article from A Randomized, Placebo-Controlled, Preoperative Trial of Allopurinol in Subjects with Colorectal Adenoma

Author

Puntoni, Matteo, primary, Branchi, Daniela, primary, Argusti, Alessandra, primary, Zanardi, Silvia, primary, Crosta, Cristiano, primary, Meroni, Emanuele, primary, Munizzi, Francesco, primary, Michetti, Paolo, primary, Coccia, Gianni, primary, De Roberto, Giuseppe, primary, Bandelloni, Roberto, primary, Turbino, Laura, primary, Minetti, Egle, primary, Mori, Marco, primary, Salvi, Sandra, primary, Boccardo, Simona, primary, Gatteschi, Beatrice, primary, Benelli, Roberto, primary, Sonzogni, Angelica, primary, and DeCensi, Andrea, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure Legend from Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial

Author

DeCensi, Andrea, primary, Puntoni, Matteo, primary, Guerrieri-Gonzaga, Aliana, primary, Cazzaniga, Massimiliano, primary, Serrano, Davide, primary, Lazzeroni, Matteo, primary, Vingiani, Andrea, primary, Gentilini, Oreste, primary, Petrera, Marilena, primary, Viale, Giuseppe, primary, Cuzick, Jack, primary, Bonanni, Bernardo, primary, and Pruneri, Giancarlo, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 1 from Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease

Author

DeCensi, Andrea, primary, Puntoni, Matteo, primary, Johansson, Harriet, primary, Guerrieri-Gonzaga, Aliana, primary, Caviglia, Silvia, primary, Avino, Franca, primary, Cortesi, Laura, primary, Ponti, Antonio, primary, Pacquola, Maria Grazia, primary, Falcini, Fabio, primary, Gulisano, Marcella, primary, Digennaro, Maria, primary, Cariello, Anna, primary, Cagossi, Katia, primary, Pinotti, Graziella, primary, Lazzeroni, Matteo, primary, Serrano, Davide, primary, Briata, Irene Maria, primary, Buttiron Webber, Tania, primary, Boni, Luca, primary, and Bonanni, Bernardo, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Data 3 from Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease

Author

DeCensi, Andrea, primary, Puntoni, Matteo, primary, Johansson, Harriet, primary, Guerrieri-Gonzaga, Aliana, primary, Caviglia, Silvia, primary, Avino, Franca, primary, Cortesi, Laura, primary, Ponti, Antonio, primary, Pacquola, Maria Grazia, primary, Falcini, Fabio, primary, Gulisano, Marcella, primary, Digennaro, Maria, primary, Cariello, Anna, primary, Cagossi, Katia, primary, Pinotti, Graziella, primary, Lazzeroni, Matteo, primary, Serrano, Davide, primary, Briata, Irene Maria, primary, Buttiron Webber, Tania, primary, Boni, Luca, primary, and Bonanni, Bernardo, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 2 from Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease

Author

DeCensi, Andrea, primary, Puntoni, Matteo, primary, Johansson, Harriet, primary, Guerrieri-Gonzaga, Aliana, primary, Caviglia, Silvia, primary, Avino, Franca, primary, Cortesi, Laura, primary, Ponti, Antonio, primary, Pacquola, Maria Grazia, primary, Falcini, Fabio, primary, Gulisano, Marcella, primary, Digennaro, Maria, primary, Cariello, Anna, primary, Cagossi, Katia, primary, Pinotti, Graziella, primary, Lazzeroni, Matteo, primary, Serrano, Davide, primary, Briata, Irene Maria, primary, Buttiron Webber, Tania, primary, Boni, Luca, primary, and Bonanni, Bernardo, primary

Published
2023
Full Text
View/download PDF

34. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study

Author

Lazzeroni, Matteo, primary, Puntoni, Matteo, additional, Guerrieri-Gonzaga, Aliana, additional, Serrano, Davide, additional, Boni, Luca, additional, Buttiron Webber, Tania, additional, Fava, Marianna, additional, Briata, Irene M., additional, Giordano, Livia, additional, Digennaro, Maria, additional, Cortesi, Laura, additional, Falcini, Fabio, additional, Serra, Patrizia, additional, Avino, Franca, additional, Millo, Francesco, additional, Cagossi, Katia, additional, Gallerani, Elisa, additional, De Simone, Alessia, additional, Cariello, Anna, additional, Aprile, Giuseppe, additional, Renne, Maria, additional, Bonanni, Bernardo, additional, and DeCensi, Andrea, additional

Published
2023
Full Text
View/download PDF

35. Abstract GS4-08: 10-year results of a phase 3 trial of low-dose tamoxifen in non-invasive breast cancer

Author

De Censi, Andrea, primary, Lazzeroni, Matteo, additional, Puntoni, Matteo, additional, Boni, Luca, additional, Gonzaga, Aliana Guerrieri, additional, Webber, Tania Buttiron, additional, Fava, Marianna, additional, Briata, Irene Maria, additional, Giordano, Livia, additional, Digennaro, Maria, additional, Cortesi, Laura, additional, Falcini, Fabio, additional, Avino, Franca, additional, Millo, Francesco, additional, Cagossi, Katia, additional, Gallerani, Elisa, additional, De Simone, Alessia, additional, Cariello, Anna, additional, Aprile, Giuseppe, additional, Renne, Maria, additional, and Bonanni, Bernardo, additional

Published
2023
Full Text
View/download PDF

37. The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients

Author

Petrera, Marilena, Paleari, Laura, Clavarezza, Matteo, Puntoni, Matteo, Caviglia, Silvia, Briata, Irene Maria, Oppezzi, Massimo, Mislej, Eva Mihajlovic, Stabuc, Borut, Gnant, Michael, Bachleitner-Hofmann, Thomas, Roth, Wilfried, Scherer, Dominique, Haefeli, Walter-E., Ulrich, Cornelia M., and DeCensi, Andrea

Published
2018
Full Text
View/download PDF

45. Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study.

Author

Bottoni, Gianluca, Fiz, Francesco, Puntoni, Matteo, Matteucci, Federica, Monti, Manuela, DeCensi, Andrea, Nanni, Oriana, Brain, Etienne, Alberini, Jean Louis, Dib, Bassam, Sacchetti, Gianmauro, Trimboli, Pierpaolo, Treglia, Giorgio, Harbeck, Nadia, Sola, Simona, Gennari, Alessandra, and Piccardo, Arnoldo

Subjects
METASTATIC breast cancer, BREAST, BREAST cancer, LYMPHATIC metastasis, LONGITUDINAL method, HISTOPATHOLOGY
Abstract

Introduction: [18F]Fluoroestradiol ([18F]FES) PET/CT has been proposed as a tool for detecting the oestrogen receptor density in patients with metastatic breast cancer (BC) non-invasively across all disease localizations. However, its diagnostic potential in terms of the detection rate (DR) of metastases is unclear. In this study, we pitted this method against [18F]FDG PET/CT and tried to identify predictors of the diagnostic superiority of the [18F] FES-based method. Materials and methods: From a multicentre database, we enrolled all patients with metastatic BC who had undergone both [18F]FES PET/CT and [18F]FDG PET/CT. Two readers assessed both images independently and used a patient-based (PBA) and lesion-based analysis (LBA) to calculate the DR. Pathology-related and clinical factors were tested as predictors of [18F]FES PET/CT superiority using a multivariate model. Results: 92 patients, bearing a total of 2678 metastases, were enrolled. On PBA, the DR of [18F]FDG and [18F]FES PET/CT was 97% and 86%, respectively (p = 0.018). On LBA, the [18F]FES method proved more sensitive than [18F]FDG PET/CT in lymph nodes, bone, lung and soft tissue (p < 0.01). This greater sensitivity was associated with lobular histology, both on PBA (Odds Ratio (OR) 3.4, 95%CI 1.0–12.3) and on LBA (OR 4.4, 95%CI 1.2–16.1 for lymph node metastases and OR 3.29, 95%CI 1.1–10.2 for bone localizations). Conclusions: The overall DR of [18F]FES PET/CT appears to be lower than that of [18F]FDG PET/CT on PBA. However, the [18F]FES method, if positive, can identify more lesions than [18F]FDG at most sites. The higher sensitivity of [18F]FES PET/CT was associated with lobular histology. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Peri-Operative Prophylaxis in Patients of Neonatal and Pediatric Age Subjected to Cardiac and Thoracic Surgery: A RAND/UCLA Appropriateness Method Consensus Study

Author

Bianchini, Sonia, Nicoletti, Laura, Monaco, Sara, Rigotti, Erika, Corbelli, Agnese, Colombari, Annamaria, Auriti, Cinzia, Caminiti, Caterina, Conti, Giorgio, De Luca, Maia, Donà, Daniele, Galli, Luisa, Garazzino, Silvia, Inserra, Alessandro, La Grutta, Stefania, Lancella, Laura, Lima, Mario, Lo Vecchio, Andrea, Pelizzo, Gloria, Petrosillo, Nicola, Piacentini, Giorgio, Pietrasanta, Carlo, Principi, Nicola, Puntoni, Matteo, Simonini, Alessandro, Tesoro, Simonetta, Venturini, Elisabetta, Staiano, Annamaria, Caramelli, Fabio, Domenico Gargiulo, Gaetano, Esposito, Susanna, Giorgio Conti (ORCID:0000-0002-8566-9365), Nicola Petrosillo, Bianchini, Sonia, Nicoletti, Laura, Monaco, Sara, Rigotti, Erika, Corbelli, Agnese, Colombari, Annamaria, Auriti, Cinzia, Caminiti, Caterina, Conti, Giorgio, De Luca, Maia, Donà, Daniele, Galli, Luisa, Garazzino, Silvia, Inserra, Alessandro, La Grutta, Stefania, Lancella, Laura, Lima, Mario, Lo Vecchio, Andrea, Pelizzo, Gloria, Petrosillo, Nicola, Piacentini, Giorgio, Pietrasanta, Carlo, Principi, Nicola, Puntoni, Matteo, Simonini, Alessandro, Tesoro, Simonetta, Venturini, Elisabetta, Staiano, Annamaria, Caramelli, Fabio, Domenico Gargiulo, Gaetano, Esposito, Susanna, Giorgio Conti (ORCID:0000-0002-8566-9365), and Nicola Petrosillo

Published
2022

50. Impact of Age and Sex Interaction on Post-Acute Sequelae of COVID-19: An Italian Cohort Study on Adults and Children.

Author

Puntoni, Matteo, Esposito, Susanna, Patrizi, Laura, Palo, Chiara Maria, Deolmi, Michela, Autore, Giovanni, Fainardi, Valentina, and Caminiti, Caterina

Subjects
*COHORT analysis, *COVID-19, *AUTOIMMUNITY, *AGE, *DISEASE complications
Abstract

Identifying factors predisposing individuals to post-acute sequelae of COVID-19 (PASC) would allow for the timely treatment of those vulnerable. Attention on the role of sex and age is growing, but published studies have shown mixed results. Our objective was to estimate the effect modification of age on sex as a risk factor for PASC. We analyzed data from two longitudinal prospective cohort studies on adult and pediatric subjects positive to SARS-CoV-2 infection that were enrolled between May 2021 and September 2022. Age classes (≤5, 6–11, 12–50, >50 years) were based on the potential role of sex hormones on inflammatory/immune and autoimmune processes. A total of 452 adults and 925 children were analyzed: 46% were female and 42% were adults. After a median follow-up of 7.8 months (IQR: 5.0 to 9.0), 62% of children and 85% of adults reported at least one symptom. Sex and age alone were not significantly associated to PASC, but their interaction was statistically significant (p-value = 0.024): the risk was higher for males aged 0–5 (females vs. males HR: 0.64, 95% CI: 0.45–0.91, p = 0.012) and for females aged 12–50 (HR: 1.39, 95% CI: 1.04–1.86, p = 0.025), especially those in the cardiovascular, neurological, gastrointestinal and sleep categories. Further research on PASC with regard to sex and age is warranted. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results